Alibaba Cloud and Zhengda Tianqing Co-Pharma, the screening accuracy can be increased by 20%
It is reported that Alibaba Cloud is working with Zhengda Tianqing to adopt AI Pharmaceuticals to alleviate the long-term and long-term pain points of traditional new drug development. Compared with traditional computer-aided drug design methods, this new method can improve the screening accuracy by 20%. Traditionally, new drugs have to go through 10-15 years of drug discovery, preclinical research, and clinical research. The drug discovery phase is the source of drug development, and its research and development efficiency directly affects the progress and efficiency of follow-up work. In the development of new international drugs, the common method for finding lead compounds is high-throughput screening, but the economic cost is high, which costs 2 to 4 million US dollars. After the discovery of lead compounds, drug chemists based on experience in drug design and compound synthesis, molecular biologists test compound activity, repeated optimization and screening, and finally found clinical candidate compounds. The time and labor cost of the drug discovery phase is high, and the establishment and application of an efficient virtual screening model can reduce labor and time costs. This time, with Alibaba Cloud's medical AI, Zhengda Tianqing obtained a brand new compound screening method. In this new method, the experimenter can establish an efficient machine learning model based on a small amount of experimental data and compound structure, and then quickly filter the molecules with high probability of inactivity, thereby enriching potential effective molecules, thereby improving research efficiency. The data results show that the screening accuracy of this machine learning model can be increased by 20% compared with the traditional computer-aided drug design method. In this regard, Alibaba Cloud Medical AI algorithm engineer Wang Cheng said: "Virtual screening through computers or high-throughput screening through experiments are carried out in existing compound libraries. For pharmaceutical companies, it is more meaningful. Breaking through the limitations of existing compound libraries, designing new structural compounds and enriching chemical space. Currently, the two companies are also co-developing compound generation algorithms for generating new compounds, forming virtual compound libraries, and expanding existing resources." In addition to working with Alibaba Cloud in AI, Zhengda Tianqing also introduced Alibaba Cloud's business mid-station architecture last year, using Internet middleware technology capabilities to accelerate the digital transformation of enterprises and improve the low-cost innovation and rapid trial and error capabilities of pharmaceutical companies. At present, it only took more than two months to complete the product development for medical digital marketing scenarios. Waist massager Waist massager Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.szmeizonscares.com